Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

ConclusionEGFR T790M mutation is a major mechanism of acquired resistance to afatinib. Osimertinib confers high response rates after afatinib failure inEGFR T790M-positive patients and its use in sequence potentially allows extended chemotherapy-free treatment.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research